Bristol makes its radiopharma move
The group’s $4.1bn swoop for RayzeBio follows big deals from Novartis and Lilly.
Christmas holiday round-up
As the biotech markets turned bullish the sector’s ups and downs continued.
Cellular Biomedicine draws a line under its past
After a rollercoaster existence Cellular Biomedicine Group has a new name, and new deals with AstraZeneca and J&J.
Like Merck, Bristol goes to China
Yet another rich ADC deal is struck as Bristol Myers Squibb ties up with China’s SystImmune.
AbbVie banishes the ghost of Stemcentrx
Yet another ADC deal sees AbbVie buy ImmunoGen, ending a 40-year rollercoaster ride with a 100% overnight premium.
Cell therapy groups double down on speedy manufacturing
Novartis and Gracell place further bets on shortened production times, with Bristol waiting in the wings.
